Fact CheckerSign in

NCT06738264Not yet recruiting

Cardiovascular Risk Factors in Rheumatoid Arthritis Patients ( Comparison Between Seronegative and Seropositive Cases )

Source: ClinicalTrials.gov · Last updated 17 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

The goal of this observational study is to learn about the long-term effects rheumatoid arthritis (RA) on cardiovascular system. The main question it aims to answer is: Does seropositive raise risk of cardiovascular diseases more than seronegative RA ?

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
12 Dec 2024
Start date
1 Jan 2025
Primary completion date
1 Sept 2025
Lead sponsor
Sohag University
NCT number
NCT06738264

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 1 Jan 2025 to the primary completion date, 1 Sept 2025
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of medications known to significantly affect cardiovascular outcomes (e.g., certain anticoagulants or anti-inflammatory agents) that are not part of standard RA treatment.

Other illness

  • Diagnosis of other significant autoimmune diseases (e.g., lupus, scleroderma).

Who the study is looking for

  • Adult patients ≥ 18 years.
  • Both sexes.
  • All patients with RA confirmed using the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology EULAR classification criteria
  • RA diagnosed for at least six months to ensure chronicity.

Age in the registry: 19 years to 75 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.